Exeltis USA, Inc. a division of the global pharmaceutical group Insud Pharma, announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Slynd™ (pronounced "slind") containing drospirenone 4 mg, an oral contraceptive tablet for pregnancy prevention.
•This award is recognition of the hard work and dedication of Silvia Gold, President of the Mundo Sano Foundation, in changing the course of Chagas disease.
•Mundo Sano is currently running the campaign Not a Single Baby with Chagas, to ensure that all babies and women of reproductive age have access to diagnosis and treatment.
•Chagas disease affects 8 million people worldwide. In Spain, there are estimated to be between 50,000 and 100,000 Chagas sufferers. Globally, almost 9,000 babies are born with Chagas disease every year.
Insud Pharma group have once again been rated “very good” in the 2018 edition of the Spanish government’s Profarma Programme, thanks to its industrial activity and commitment to R&D.
BioDan, a 3D dressing derived from human skin which can be bioprinted and frozen, Brainguard, a wearable system that predicts migraines, and Insulclock, a system which monitors and controls the treatment of diabetes patients are the three startups selected in the second round of the ChemoStart accelerator programme, which seeks to support innovative, disruptive solutions that improve people’s health and wellbeing.
The ChemoStart Programme is an initiative by Insud Pharma, spearheaded by Leandro Sigman, to support innovative healthcare startups
In the second edition of the programme, 12 finalists have been shortlisted to present to a panel of experts at the Pitch Day on Thursday 31 January
The outstanding efforts of the 300 workers at Química Sintética - a pharmaceutical manufacturer which forms part of the pharmaceutical company Chemo - have been recognised through three awards presented by FEIQUE, the Business Federation for the Spanish Chemical Industry, at the 2nd RSE Awards for the Chemical Sector.
Exeltis has received acceptance from the US Food and Drug Administration (FDA) of the filing of Slinda® (4mg Drospirenone-only pill), the novel oral contraceptive developed by the company. The Prescription Drug User Fee Act (PDUFA) date is expected during the 27 May of 2019.
The pharmaceutical group Insud Pharma has just kicked off the second round of its startup programme #CHEMOSTART!, which aims to help get innovative health projects off the ground and offer additional support to projects which are already up and running.
The prestigious scientific journal The Lancet Gastroenterology and Hepatology journal has published the results of the comparative study of pharmacokinetics, efficacy, safety and immunogenicity of bevacizumab biosimilar BEVZ92 in combination with FOLFOX or FOLFIRI, as the first-line treatment for metastatic colorectal cancer versus the original reference product.